LSK BioPharma
Health care product development company
About LSK BioPharma
Elevar Therapeutics, operating in the biopharmaceutical sector, focuses on the clinical development of innovative therapies for unmet medical needs in cancer. The company is developing two proprietary drug candidates: Rivoceranib (Apatinib), a VEGFR-2 inhibitor showing clinical efficacy in various solid tumors, and a BTK/JAK3 inhibitor with potential applications in hematologic malignancies and rheumatoid arthritis. Elevar Therapeutics serves patients with solid tumor cancers such as gastric, colorectal, adenoid cystic carcinoma, and hepatocellular carcinoma. The company operates globally, holding worldwide rights for Rivoceranib, excluding China, and has partnered for development and marketing in South Korea. Elevar Therapeutics generates revenue through the development, licensing, and commercialization of its drug candidates, aiming for regulatory approvals and market entry. The business model is centered around advancing clinical trials, securing regulatory approvals, and forming strategic partnerships to bring their therapies to market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2005
- Headquarters
- Salt Lake City, United States
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 22.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jul 2018 | $20M | $80M | Undisclosed | — |
Growth signals
Latest recorded traffic for LSK BioPharma is 0 monthly website visits. LSK BioPharma's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
LSK BioPharma in the Salt Lake City ecosystem
The LSK BioPharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about LSK BioPharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LSK BioPharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









